Medication is an additional source of phosphate intake in chronic kidney disease patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 10, 2015, Pages 959-967

  Sultana, J ^a   Musazzi, U M ^b   Ingrasciotta, Y ^a   Giorgianni, F ^a   Ientile, V ^a   Fontana, A ^c   Minghetti, P ^b   Perrotta, M ^d   Santoro, D ^a   Savica, V ^a   Trifiro G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d Caserta 1 Local Health Service   (Italy)

Author keywords

Cardiovascular risk; Chronic kidney disease; Drugs; Observational study; Phosphate

Indexed keywords

INSULIN; PHOSPHATE; PHOSPHATE CONTAINING MEDICINAL PRODUCT; SEX HORMONE; UNCLASSIFIED DRUG; URINARY TRACT AGENT; CARDIOVASCULAR AGENT; GASTROINTESTINAL AGENT; PRESCRIPTION DRUG;

ARTICLE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MORBIDITY; PHOSPHATE INTAKE; PRESCRIPTION; PRIORITY JOURNAL; UROGENITAL SYSTEM; CARDIOVASCULAR DISEASES; CHEMISTRY; CHRONIC KIDNEY FAILURE; COMPLICATION; ITALY; RISK FACTOR;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GASTROINTESTINAL AGENTS; HUMANS; HYPERPHOSPHATEMIA; ITALY; PHOSPHATES; PRESCRIPTION DRUGS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84941943427     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.06.001     Document Type: Article

References (24)

1. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109(6):697-711.
2. Fouque D., Wang P., Laville M., Boissel J.P. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000, 15(12):1986-1992.
3. Savica V., Calò L.A., Monardo P., Caldarera R., Cavaleri A., Santoro D., et al. High phosphate content beverages in dialysis patients: relevance for hyperphosphatemia and cardiovascular risk. Nutr Metab Cardiovasc Dis 2008, 18(8):e39-40.
4. Trifirò G., Corrao S., Alacqua M., Moretti S., Tari M., Caputi A.P., et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006, 62(5):582-590. UVEC Group.
5. Trifirò G., Savica R., Morgante L., Vanacore N., Tari M., Moretti S., et al. Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. Park Relat Disord 2008, 14(5):420-425.
6. Alacqua M., Trifirò G., Cavagna L., Caporali R., Montecucco C.M., Moretti S., et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008, 59(4):568-574.
7. Trifirò G., Sultana J., Giorgianni F., Ingrasciotta Y., Buemi M., Muscianisi M., et al. Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. Biomed Res Int 2014, 2014:268362.
8. Ingrasciotta Y., Sultana J., Giorgianni F., Caputi A.P., Arcoraci V., Tari D.U., et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One 2014, 9(2):e89072.
9. Isakova T., Wahl P., Vargas G.S., Gutiérrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
10. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19(3):429-435.
11. Chartsrisak K., Vipattawat K., Assanatham M., Nongnuch A., Ingsathit A., Domrongkitchaiporn S., et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol 2013, 14:14.
12. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
13. Scialla J.J., Xie H., Rahman M., Anderson A.H., Isakova T., Ojo A., et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014, 25:349-360. Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.
14. Jimbo R., Kawakami-Mori F., Mu S., Hirohama D., Majtan B., Shimizu Y., et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency. Kidney Int 2014, 85:1103-1111.
15. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. J Am Med Assoc 2011, 305:2432-2439. Chronic Renal Insufficiency Cohort (CRIC) Study Group.
16. Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J Am Med Assoc 2011, 305(11):1119-1127.
17. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano J.M., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167(9):879-885.
18. George J., Majeed W., Mackenzie I.S., Macdonald T.M., Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. Br Med J 2013, 347:f6954.
19. Food and Drug Administration. Sodium Phosphate Over-the-Counter Products: Drug Safety Communication - Possible Harm From Exceeding Recommended Dose. Available from: [accessed 30.09.14]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm380833.htm.
20. European Commission: Enterprise and Industry Directorate-General. Available from: [accessed 20.09.14]. http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
21. Uribarri J., Calvo M.S. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?. Semin Dial 2003 May-Jun, 16(3):186-188.
22. Cupisti A, D'Alessandro C, Valeri A, Capitanini A, Meola M, Betti G, et al. Food intake and nutritional status in stable hemodialysis patients. Ren Fail 2010;32(1):47e54.
23. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, Kovesdy CP, Bross R, Shinaberger CS, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010 Mar;5(3):519-30.
24. Da J, Xie X, Wolf M, Disthabanchong S, Wang J, Zha Y, et al. Serum phosphorus and progression of CKD and mortality: a metaanalysis of cohort studies. Am J Kidney Dis 2015 Mar 21. pii: S0272-6386(15) 00406e0.